• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

理解疫苗效力时的注意事项。

Considerations in Understanding Vaccine Effectiveness.

作者信息

Lau Chin Shern, Aw Tar Choon

机构信息

Department of Laboratory Medicine, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore.

Department of Medicine, National University of Singapore, Singapore 117599, Singapore.

出版信息

Vaccines (Basel). 2022 Dec 22;11(1):20. doi: 10.3390/vaccines11010020.

DOI:10.3390/vaccines11010020
PMID:36679865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9864852/
Abstract

Although vaccine effectiveness reports are essential to assessing policies on SARS-CoV-2 vaccination, several factors can affect our interpretation of the results. These include the waning of antibodies, the prevailing viral variants at the time of the study, and COVID-19 disease prevalence in the population. Disease prevalence significantly impacts absolute risk reduction and could skew expected efficacy when increased disease prevalence inflates the absolute risk reduction in the face of a constant relative risk reduction. These factors must be considered in the interpretation of vaccine effectiveness to better understand how vaccines can improve disease prevention among the population. We highlight the impact of various factors on vaccine effectiveness.

摘要

尽管疫苗有效性报告对于评估新冠病毒疫苗接种政策至关重要,但有几个因素会影响我们对结果的解读。这些因素包括抗体水平下降、研究期间流行的病毒变体以及人群中的新冠疾病患病率。疾病患病率会显著影响绝对风险降低率,当疾病患病率增加导致绝对风险降低率在相对风险降低率不变的情况下被夸大时,可能会使预期疗效产生偏差。在解读疫苗有效性时必须考虑这些因素,以便更好地理解疫苗如何在人群中改善疾病预防。我们强调了各种因素对疫苗有效性的影响。

相似文献

1
Considerations in Understanding Vaccine Effectiveness.理解疫苗效力时的注意事项。
Vaccines (Basel). 2022 Dec 22;11(1):20. doi: 10.3390/vaccines11010020.
2
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2(Delta)变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络,2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
3
COVID-19 vaccine effectiveness and variants in Nepal: study protocol for a test-negative case-control study with SARS-CoV-2 genetic sequencing.尼泊尔的 COVID-19 疫苗有效性和变异体:一项使用 SARS-CoV-2 基因测序的病例对照研究方案。
BMJ Open. 2023 Apr 18;13(4):e068334. doi: 10.1136/bmjopen-2022-068334.
4
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性:一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
5
SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.接种加强针后感染 SARS-CoV-2:一项前瞻性、基于社区的病例对照研究中的疾病和症状特征。
J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28.
6
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.2022 年至 2023 年秋冬期间,老年欧洲人群中的 COVID-19 疫苗有效性。
JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258.
7
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.在印度 delta(B.1.617.2)变异株流行期间,ChAdOx1 nCoV-19 疫苗对 SARS-CoV-2 感染的有效性:一项基于病例对照研究的疫苗效力评估和接种后免疫反应的机制研究。
Lancet Infect Dis. 2022 Apr;22(4):473-482. doi: 10.1016/S1473-3099(21)00680-0. Epub 2021 Nov 25.
8
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用:来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
9
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.关于二价加强针相对于单价加强针或初始疫苗接种周期在 SARS-CoV-2 疫苗功效方面的真实世界证据:叙述性综述。
Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081.
10
Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study.评估 SARS-CoV-2 变异株对美国 COVID-19 疫情和社会恢复的影响:一项数学建模研究。
Front Public Health. 2022 Jan 10;9:801763. doi: 10.3389/fpubh.2021.801763. eCollection 2021.

引用本文的文献

1
The Effectiveness of Four Quadrivalent, Inactivated Influenza Vaccines Administered Alone or in Combination with Pneumococcal and/or SARS-CoV-2 Vaccines: A Population-Wide Cohort Study.四种四价灭活流感疫苗单独接种或与肺炎球菌和/或SARS-CoV-2疫苗联合接种的有效性:一项全人群队列研究。
Vaccines (Basel). 2025 Mar 13;13(3):309. doi: 10.3390/vaccines13030309.
2
Time-varying effects of COVID-19 vaccination on symptomatic and asymptomatic infections in a prospective university cohort in the USA.美国一所大学前瞻性队列研究中COVID-19疫苗接种对有症状和无症状感染的时变效应。
BMJ Open. 2025 Feb 22;15(2):e084408. doi: 10.1136/bmjopen-2024-084408.

本文引用的文献

1
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.用二价疫苗中和BA.4-BA.5、BA.4.6、BA.2.75.2、BQ.1.1和XBB.1
N Engl J Med. 2023 Mar 2;388(9):854-857. doi: 10.1056/NEJMc2214916. Epub 2023 Jan 25.
2
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.奥密克戎变异株流行期间 SARS-CoV-2 突破性感染和再感染的传染性。
Nat Med. 2023 Feb;29(2):358-365. doi: 10.1038/s41591-022-02138-x. Epub 2023 Jan 2.
3
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
4
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.二价 mRNA 疫苗预防有症状的 SARS-CoV-2 感染的效果-增加社区获得检测的项目,美国,2022 年 9 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526-1530. doi: 10.15585/mmwr.mm7148e1.
5
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.接种 BNT162b2 疫苗加强针 5 个月后老年人对 Delta 和奥密克戎变异株特异性抗体滴度的下降
Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022.
6
Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster.同源接种科兴新冠疫苗与BNT162b2疫苗后90天内的中和及总/IgG刺突抗体反应。
Antibodies (Basel). 2022 Nov 8;11(4):70. doi: 10.3390/antib11040070.
7
The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study.三剂灭活 COVID-19 疫苗接种在健康献血者中的抗体反应持续时间和广度:一项观察性研究。
Front Immunol. 2022 Nov 1;13:1027924. doi: 10.3389/fimmu.2022.1027924. eCollection 2022.
8
BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5.BNT162b2疫苗对新冠病毒奥密克戎BA.4和BA.5的有效性
Lancet Infect Dis. 2022 Dec;22(12):1663-1665. doi: 10.1016/S1473-3099(22)00692-2. Epub 2022 Oct 25.
9
210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine.3剂BNT162b2 mRNA疫苗全程接种后总抗体、IgG抗体及中和刺突抗体的210天动力学
Vaccines (Basel). 2022 Oct 12;10(10):1703. doi: 10.3390/vaccines10101703.
10
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.针对美国与 COVID-19 相关住院的初级系列和加强剂量疫苗有效性:基于阴性设计的实时研究。
BMJ. 2022 Oct 11;379:e072065. doi: 10.1136/bmj-2022-072065.